Dr. Lohr obtained his MD and PhD in Immunology at the Ruprecht-Karls University, Heidelberg, Germany. He conducted postdoctoral research in immunology and subsequently trained in Internal Medicine at UCSF. He completed a Hematology/Oncology fellowship at Dana–Farber Institute (Harvard Medical School), received further training in cancer genomics, and joined Dana Farber and the Broad Institute as an Assistant Professor of Medicine in 2016.

His research interests are in multiple myeloma and cellular therapies, and he leads successful independent translational research programs in these areas. In addition to his responsibilities as CellReGen director, he has also been appointed Director of Immunotherapy research and is an Associate Professor in the Division of Hematology and Hematologic Malignancies.